Retrospective Study
Copyright ©The Author(s) 2016.
World J Gastroenterol. Feb 14, 2016; 22(6): 2126-2132
Published online Feb 14, 2016. doi: 10.3748/wjg.v22.i6.2126
Table 1 Patients and tumor characteristics
VariableNo. of patients, n = 18
Patient characteristics
Age (yr), median (range)54 (21-74)
Sex (male)10
Pre-operative CEA level (μg/L), median (range)26.3 (1-860)
Primary tumor site
Colon2
Rectum16
Symptoms caused by the primary tumor13
Symptoms at the time of presentation
None5
Rectal blood loss7
Changes in bowel habits6
AJCC T-stage on pathology
ypT1/ypT21
ypT3/ypT415
Lymph node status on pathology
ypN1/ypN214
ypN02
Hepatic metastasis
Size of largest metastasis (cm), median (range)4 (2-16)
No. of metastasis, median (range)4 (1-12)
Location (unilobular)11
CRS score
< 32
≥ 316
Preoperative chemotherapy14
Cycles, median (range)3 (0-5)
Indication
Conversion4
Locally advanced liver metastases10
Regimens of preoperative chemotherapy
Oxaliplatin10
Irinotecan4
Cetuximab4
Bevacizumab2
Response of preoperative chemotherapy
PR9
SD4
PD1
Table 2 Details of the surgical procedures and early outcomes
VariableNo. of patients, n = 18
Type of hepatic resection
Major14
Minor4
Extent of hepatic resection
Partial10
Hemihepatectomy3
Extended hepatectomy5
Type of colorectal resection
Low anterior resection12
Abdominoperineal resection2
Left hemicolectomy2
Resected lymph nodes, median (range)11 (6-20)
Complications
Hepatectomy-related
hydrothorax3
Abdominal abscess1
Minor (Clavien grade < 3)4
Major (Clavien grade ≥ 3)0
Post-operative mortality (within 90 d)0
Surgery on primary cancer
Anastomotic leakage1
Abdominal abscess2
Minor (Clavien grade < 3)3
Major (Clavien grade ≥ 3)0
Post-operative mortality (within 90 d)0
Table 3 Characteristics of 18 patients who underwent the formalized treatment plan
PatientLargest size (cm)CEA level (μg/L)cTNNo. of metsCTxResponseon CTxLiver surgeryRTxPrimary surgery
116861.4cT3N11XeloxPDHemihepNoneLeft Hemicol
221cT4N24FolfoxPRExtended hemihepNoneLAR
33.513.4cT4N11NoneNonePartial30 Gy/XelodaLAR
46113.4cT3N15FolfoxSDPartialNoneLeft Hemicol
52.516.8cT3N16XeloxPRExtended hemihep30 Gy/XelodaNone
67.930.4cT4N14XeloxPRExtended hemihepNoneLAR
743.2cT2N13Folifiri + CetPRHemihepNoneLAR
82.42.4cT3N23Folifiri + CetPRPartial50 Gy/XelodaLAR
9578.1cT4N21NoneNonePartial50 Gy/XelodaAPR
103.8160.9cT3N21FolfoxSDPartialNoneAPR
1143.7cT3N06Folifiri + CetPRPartial30 Gy/XelodaLAR
121.519.7cT3N14Folfox + BevPRPartialNoneLAR
138.587.2cT3N15NoneNonePartialNoneLAR
141222.1cT4N16Folfox + CetPRHemihepNoneLAR
15679.4cT3N13FolfoxiriSDExtended hemihepNoneLAR
164.36.1cT3N012Xelox + BevPRPartialNoneLAR
17334.7cT3N12NoneNonePartialNoneLAR
183.539.0cT3N26XeloxSDExtended hemihep50 Gy/XelodaNone